echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > CellCarta acquires next-generation immuno-MRM assay

    CellCarta acquires next-generation immuno-MRM assay

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>/* Style Definitions */ sp.


    MONTREAL , May 20, 2022 /PRNewswire/ -- CellCarta, a leading global provider of precision medicine laboratory services, today announced the acquisition of the commercial rights to Precision Assays antibody panels and assa.

    Precision Assays is a leader in next-generation targeted proteomic detection solutio.

    Precision Assays, a spin-off from the Fred Hutchinson Cancer Research Center ("Fred Hutchinson Center"), develops and deploys high-end multiplex quantification for customers in the pharmaceutical and biotechnology industries Immuno-MRM mass spectrometry detecti.

    CellCarta_CellCarta_expands_it_proteomics_portfolio_with_the_acq

    The acquisition of Precision Assays, a large-scale targeted mass spectrometry assay characterized according to the National Cancer Institute Clinical Proteomics Tumor Analysis Consortium (CPTAC) Level 2 Guidelines, greatly expands CellCarta's capabilities in off-the-shelf multiplex protein quantitation products that can Direct use in immuno-oncology clinical and preclinical resear.

    " Precision Assays ' extensive robust assays characterized according to CPTAC guidelines, along with mature proof-of-concept data, will enable CellCarta to confidently <.



    CellCarta 's expertise in protein quantification, these immuno- MRM samples can be further validated to support secondary and primary clinical endpoints, " said Chief Operating Officer, CellCarta Immunology and Proteomics Business Unit Lorella Di Donato said <.


    Paulovich said: " CellCarta , a global contract research organization with expertise in targeted mass spectrometry and biomarker detection, will serve as an ideal partner to deploy and industrialize our platform to support discovery, translational and clinical research, Especially in the fields of precision medicine and immuno-oncolo.


    CellCarta_CellCarta_expands_it_proteomics_portfolio_with_the_acq
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.